Aenova was founded in 2008. However, the companies that belong to the Group today have been successfully active on the market for decades. Which means we can look back on almost a century of industry experience.

 In 2008 the pharmaceutical companies Dragenopharm and Swiss Caps merge to form the nucleus of the Group. The company headquarters are established in Pähl, Munich. The Group initially has seven production sites in five countries (Germany, Switzerland, France, Romania, and the USA). Around 1,600 employees work to produce solid dosage forms such as soft gelatin capsules, hard capsules, tablets, film-coated tablets, dragées, and effervescent tablets.

In 2012 the Temmler Group is acquired. Temmler is specialized in the production of ointments, gels, and drops and brings new service segments, including the manufacture of clinical test material, distribution logistics, and out-licensing business to the Group. Around 1,000 people are employed at seven production sites in Germany, Switzerland, Italy, and Ireland and are integrated into existing Aenova business.

The acquisition of Euro Vital Pharma also takes place in 2012. The company has more than 30 pharmaceuticals approved for the German market as well as dietary supplements and cosmetic products in the portfolio and thus strengthens the Aenova "private label" field.

At the beginning of 2014 the merger with Haupt Pharma under the umbrella of the Aenova Group takes place. This move expands the Group's global production network by seven additional sites with 2,000 employees. The existing Aenova portfolio in the field of solid, semi-solid, and liquid dosage forms can be extended to include sterile production and the processing of special materials such as hormones, antibiotics, and cytostatics, among other fields.

The Group's full-service offer now covers all product groups and all crucial dosage forms in the field of pharmaceutical products and dietary supplements. The integration of Haupt Pharma into the Aenova Group in 2015 increased the annual turnover by 2.6% to € 727 million.

> 2008

Merger of the Aenova Group

> 2010

Founding of competence centers for soft capsules technology (Kirchberg, Switzerland), powder technology (Tittmoning, Germany), and packaging technology (Bad Aibling, Germany)

> 2011

Opening of a new high-performance production facility in Tittmoning (Germany)

> 2011

Construction of own research and development unit

> 2012

Acquisition of the Temmler Group and Euro Vital Pharma

> 2012

Opening of a new production facility for effervescent products in Bad Aibling (Germany)

> 2012

Financial investor BC Partners acquires the majority stake in the Aenova Group from Bridgepoint and other shareholders. Funds advised by BC Partners support the continued growth of the Group with capital and strategic expertise

> 2012

Expansion of development capacity with a new laboratory in Muttenz (Switzerland)

> 2013

Acquisition of the Haupt Pharma Group

> 2014

Formation of inter-site Technology Excellence Groups